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Abstract
Background—Many patients have unexplained persistent dyspnea after negative computed 
tomographic pulmonary angiography (CTPA). We hypothesized that many of these patients have 
isolated right ventricular (RV) dysfunction from treatable causes. We previously derived a clinical 
decision rule (CDR) for predicting RV dysfunction consisting of persistent dyspnea and normal 
CTPA, finding that 53% of CDR-positive patients had isolated RV dysfunction. Our goal is to 
validate this previously derived CDR by measuring the prevalence of RV dysfunction and 
outcomes in dyspneic emergency department patients.
Methods—A secondary analysis of a prospective observational multicenter study that enrolled 
patients presenting with suspected PE was performed. We included patients with persistent 
dyspnea, a nonsignificant CTPA, and formal echo performed. Right ventricular dysfunction was 
defined as RV hypokinesis and/or dilation with or without moderate to severe tricuspid 
regurgitation.
Results—A total of 7940 patients were enrolled. Two thousand six hundred sixteen patients were 
analyzed after excluding patients without persistent dyspnea and those with a significant finding 
on CTPA. One hundred ninety eight patients had echocardiography performed as standard care. Of 
those, 19% (95% confidence interval [CI], 14%–25%) and 33% (95% CI, 25%–42%) exhibited 
RV dysfunction and isolated RV dysfunction, respectively. Patients with isolated RV dysfunction 
or overload were more likely than those without RV dysfunction to have a return visit to the 
emergency department within 45 days for the same complaint (39% vs 18%; 95% CI of the 
difference, 4%–38%).
Conclusion—This simple clinical prediction rule predicted a 33% prevalence of isolated RV 
dysfunction or overload. Patients with isolated RV dysfunction had higher recidivism rates and a 
trend toward worse outcomes.
1. Introduction
Dyspnea is a common complaint encountered in the emergency department (ED), 
accounting for more than 3 million ED visits annually in the United States [1]. Management 
remains difficult because dyspnea has many etiologies requiring varied treatment, and 
clinicians fail to identify the cause in nearly one-half of ED patients [2]. Imaging with 
computed tomographic pulmonary angiography (CTPA) is commonly used in the ED to 
evaluate for pulmonary embolism (PE) [3,4], and also provides additional alternative 
diagnostic information [5].
Assessment of persistently symptomatic patients after a negative CTPA continues to pose a 
challenge for clinicians. Kline et al [6] found that 40% of patients who receive one CTPA to 
evaluate for possible PE underwent a second CTPA, which seldom demonstrated an 
actionable diagnosis. Because patients who have persistent dyspnea are more likely to return 
for repeat evaluation and undergo repeated nondiagnostic CTPA in the near term, 
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determining the cause of dyspnea may help guide the disposition of ED patients after a 
negative CTPA.
Many patients with dyspnea have evidence of coincident right ventricular (RV) dysfunction 
or overload. Right ventricular dysfunction may originate from intrinsic muscle damage 
caused by ischemia or cardiomyopathies. More commonly, however, RV dysfunction occurs 
from increases in RV after load, caused by treatable etiologies such as chronic obstructive 
pulmonary disease, obstructive sleep apnea, pulmonary arterial hypertension, or pulmonary 
hypertension secondary to left heart disease or chronic thromboemboli [7–13]. Detection of 
RV dysfunction from pulmonary hypertension is frequently under diagnosed. Once 
recognized, it is usually associated with a delay in evaluation and treatment [7,8,14,15]. 
Patients with underlying RV dysfunction, including RV dilation with or without RV 
hypokinesis, have increased morbidity and mortality [7,12]. In ED patients with dyspnea, 
RV dilation is an independent predictor of 1-year mortality [16].
In our derivation article [17], we derived a simple clinical decision rule (CDR) to identify 
patients with a high probability for isolated RV dysfunction or overload. This rule was 
derived from both inpatients and ED patients who were all adults older than 17 years and 
who underwent CTPA for suspected PE. The final rule consisted of persistent dyspnea plus a 
normal CTPA scan. With a positive rule, 22 (53%) of 41 (95% confidence interval [CI], 
37%–69%) patients with transthoracic echocardiography performed had isolated RV 
dysfunction or overload. In the derivation cohort, when broadening normal CTPA, which 
excluded patients with underlying chronic diseases such as emphysema or cardiomegaly, to 
“CTPA without acute process”, the CDR predicted 64 (36%) of 179 (95% CI, 29%–43%) 
patients to have isolated RV dysfunction or overload. These results were similar to the 30% 
prevalence of RV dysfunction in dyspneic patients reported by Chen et al [16] in the PRIDE 
study, which examined ED patients with shortness of breath, but was not restricted to those 
who had CTPA.
Given the importance of RV function on outcomes in a variety of disease states, we believe 
that early identification and initiation of therapy targeted at the cause of isolated RV 
dysfunction or overload, if possible, may improve outcome.
The aim of this study was to test the external validity of the previously derived CDR by 
measuring the prevalence of isolated RV dysfunction or overload and outcomes in ED 
patients with persistent shortness of breath and CTPA without acute process.
2. Methods
2.1. Study design and setting
This study was a secondary analysis of the Pulmonary Embolism Rule Out Criteria (PERC) 
database, a prospective observational study involving 12 EDs, that collected data on patients 
presenting to the ED with suspected PE. Institutional review boards approval was obtained at 
all participating hospitals. The methods from this study have been published previously [18].
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2.2. Selection of participants
Patients were enrolled from July 1, 2003, until November 30, 2006. For our main analysis, 
we included ED patients with persistent shortness of breath, CTPA without acute process, 
and formal echocardiography performed. Persistent dyspnea was defined as patient’s 
ongoing subjective feeling of shortness of breath at rest while breathing room air, during the 
index ED visit or hospital stay. “CTPA without acute process” was defined as a CTPA 
without evidence of PE, pulmonary infiltrate, thoracic malignancy, pneumothorax, aortic 
dissection, aortic aneurysm, or congestive heart failure. Exclusion criteria were patients 
without a history or complaint of shortness of breath or persistent shortness of breath, 
patients with a CTPA positive for PE or other acutely significant CT findings, patients with 
an admission and/or discharge diagnosis of PE, and patients without an echocardiography 
performed.
2.3. Study protocol
Patients were deemed eligible for enrollment if a diagnostic test for PE was ordered by or 
under the supervision of a board-certified emergency physician. The decision to order this 
test followed standard care and was based on history and physical examination findings. 
Diagnostic tests for PE included CTPA scan, pulmonary angiography, and ventilation-
perfusion lung scanning. Patients were excluded if they had a known diagnosis of PE found 
on pulmonary vascular imaging performed in the previous 7 days or if they were at risk for 
loss to follow-up (eg, homeless, international travelers, and prisoners). Study enrollment 
varied by site and consisted of consecutive enrollment or random selection in 8-hour blocks 
of time with subsequent medical record review of eligible but unenrolled patients.
2.3.1. Clinical data—Treating clinicians collected and recorded data concurrently with 
routine patient care and prior to the clinician knowing the results of diagnostic tests. Data 
were collected on a standardized, Web-based form, with more than 65 data points.
2.3.2. Computed tomographic pulmonary angiography interpretation—The 
radiology department at each individual institution regulated scanning protocols. All data 
collected were from final interpretations by a board-certified radiologist. A diagnosis of PE 
was made if a pulmonary arterial filling defect was detected by the interpreting radiologist 
and identified as an acute PE.
2.3.3. Transthoracic echocardiography—All echocardiograms were performed at the 
discretion of the clinical care team. All institutions had facilities with Intersocietal 
Commission for the Accreditation of Echocardiography Laboratories accreditation, and 
board-certified cardiologists with echocardiography fellowship training provided final 
written interpretations of echocardiograms. Accordingly, all reports included estimate of left 
ventricular (LV) ejection fraction; an estimate of tricuspid regurgitation (TR) graded as 
none, mild, moderate, or severe; a Doppler measurement of tricuspid jet velocity (if 
obtainable); and a qualitative assessment of RV size (normal or enlarged) and function 
(normal or hypokinetic). Transthoracic echocardiography was categorized into 5 categories 
including the following: (1) normal LV and RV size and function, (2) LV ejection fraction 
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(LVEF) less than 45%, (3) isolated moderate to severe TR, (4) isolated RV hypokinesis and 
dilation, or (5) RV hypokinesis and dilation with moderate to severe TR.
2.3.4. Follow-up—Patients were followed up at 45 days postenrollment for outcome. All 
data, including explicit terms of LV and RV function, were abstracted by trained 
coordinators and transferred into a Web-based data collection instrument [19]. Direct patient 
contact was via telephone or mail, supplemented as needed by the medical record and/or a 
death registry review [18].
2.4. Data analysis
We compared means and bivariate frequencies measured in patients with and without 
echocardiography and in patients with and without isolated RV dysfunction or overload. 
Means were compared with an unpaired t test, and bivariate frequencies were compared with 
a χ2 test. Our main analysis was the point estimate of the prevalence of isolated RV 
dysfunction or overload observed in persistently short of breath patients with a CTPA 
negative for PE or other significant finding and formal transthoracic echocardiography 
performed. Right ventricular dysfunction or overload was defined as RV hypokinesis and/or 
dilation with or without moderate to severe TR. Isolated RV dysfunction or overload was 
defined as RV dysfunction in the absence of LV systolic dysfunction.
We calculated percentages of RV dysfunction and isolated RV dysfunction or overload in 
those patients with a positive decision rule and echocardiography, with 95% CIs from the 
exact binomial formula (Stats Direct, v 2.7.9, Cheshire, England, UK). Statistical 
significance was accepted for P < .05.
3. Results
A total of 7940 patients were enrolled from the PERC database. Of these, 4784 patients were 
excluded because they did not meet the criteria for persistent dyspnea or did not have a 
CTPA scan performed. Five hundred forty patients were then excluded because their CTPA 
was positive for a PE or other acute process. Of the remaining 2616 patients included for 
analysis, 198 had formal transthoracic echocardiography performed. Figure shows a flow 
diagram of patients meeting the inclusion criteria. Table 1 shows patient characteristics 
comparing all enrolled patients with and without echocardiography. Overall, patients with 
echocardiography were older, were admitted to a higher level of care, and had more 
cardiovascular disease.
Analysis of the 198 patients with echocardiography (Table 2) yielded 38 (19%; 95% CI, 
14%–25%) patients with evidence of RV dysfunction or overload, including RV dilation 
and/or hypokinesis with or without moderate to severe TR. One hundred sixty (81%; 95% 
CI, 74%–85%) patients had no evidence of RV dysfunction or overload; 53% were female. 
Compared with patients without RV dysfunction, patients with evidence of RV dysfunction 
or overload on echocardiography were more likely to be sicker, with 18% vs 7% (95% CI, of 
the difference, 0.4%–26%) being admitted to the intensive care unit (ICU), and tended to 
have a greater history of wheezing and tobacco use.
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Of the 198 patients with an echocardiogram, 115 had normal LVEF, defined as ejection 
fraction greater than 45%. Thirty-five (30%; 95% CI, 23%–39%) of the patients with normal 
LVEF had moderate to severe TR without RV dilation. Thirty-eight (33%; 95% CI, 25%–
42%) of the 115 patients with normal LVEF had isolated RV dysfunction or overload, 14 
with RV dilation and moderate to severe TR and 24 with RV dilation without significant TR.
Table 3 compares outcomes of patients with and without isolated RV dysfunction or 
overload on echocardiography. Patients with RV dysfunction or overload were more likely to 
have a return visit to the ED within 45 days for the same complaint (39% vs 18%; 95% CI of 
the difference, 4%–38%) and tended to have more repeat CTPA scans within 45 days (10% 
vs 5%; 95% CI of the difference, −4% to 19%) and a higher mortality rate (16% vs 5%; 95% 
CI of the difference, −0.5% to 25%). Also, patients with isolated RV dysfunction or overload 
were more often discharged with a primary diagnosis of pulmonary hypertension (P < .05) 
than those patients without evidence of RV dysfunction or overload (Table 3).
4. Discussion
Unexplained RV dysfunction or overload was found to have a prevalence of 19% (95% CI, 
14%–25%) in persistently dyspneic ED patients with a nonsignificant CTPA. The prevalence 
of RV dysfunction or overload increased to 33% (95% CI, 25%–42%) when excluding 
patients with abnormal LVEF.
Prior research has looked to define the prevalence of RV dysfunction in ED patients 
presenting with dyspnea. The PRIDE study looked to determine the use of N-terminal pro-
brain natriuretic peptide (NT-proBNP) compared with echocardiographic parameters in ED 
patients with shortness of breath. In the PRIDE study, 134 (23%) of 599 dyspneic patients 
had an echocardiogram. Similar to our study, patients who received an echocardiography in 
the PRIDE study had more severe symptoms and were more likely to have a history of heart 
disease. Interestingly, 30% of these patients had changes in RV fractional area or RV 
dilation, 20% had RV hypokinesis, and 30% had moderate or severe TR [16].
Our derivation article found that patients with a positive CDR (consisting of persistent 
dyspnea and normal CTPA) and echocardiography performed as routine management 
exhibited a prevalence of isolated RV dysfunction or overload of 53% (95% CI, 37%–69%). 
This number decreased to a prevalence of 36% (95% CI, 29%–43%) when broadening the 
definition of normal CTPA (which excluded patients with underlying chronic diseases such 
as emphysema) to CTPA without acute process. This latter definition more accurately 
reflects the definition of negative CTPA used in this article.
Both the PRIDE and derivation studies show a similar prevalence of isolated RV dysfunction 
or overload, comparable to the current work, but comprise a different heterogeneous 
population and subset of data. Our study differs from the PRIDE study, however, in that we 
further risk stratified patients using CTPA to rule out PE or other significant findings. 
Furthermore, because LV failure is a leading cause of RV dysfunction [20], we examined the 
prevalence of isolated RV dysfunction or overload by excluding patients with an abnormal 
LVEF. In the derivation study, we defined isolated RV dysfunction or overload by excluding 
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patients with both systolic and/or diastolic LV dysfunction. However, in the present work, 
we were unable to exclude patients with LV diastolic dysfunction because this secondary 
analysis lacked echocardiographic information on LV diastolic function. Nonetheless, the 
prevalence of isolated RV dysfunction or overload is similar in the derivation and validation 
samples (36% vs 33%, respectively).
Prior literature has shown that patients with RV dysfunction or overload have worse 
outcomes. In patients with left heart failure or COPD, RV dysfunction or overload is 
associated with increased acute exacerbations and increased hospital readmissions compared 
with patients with normal RV function [7,21,22]. Patients with pulmonary hypertension 
complicated by RV dysfunction generally have a significantly poorer prognosis and 
decreased longevity [12,13,15].
This study corroborates findings in the derivation study showing a trend toward higher rates 
of return visits with repeat CTPA scanning among patientswith isolated RV dysfunction or 
overload. In the present study, patients with isolated RV dysfunction or overload had 
statistically significant higher rates of ICU admissions and return visits within 45 days for 
the same complaint. They also exhibited higher mortality rates and higher rates of repeat 
chest imaging within 45 days, but these outcomes did not reach statistical significance. 
Patients with RV dysfunction or overload were more likely to be diagnosed at hospital 
discharge with pulmonary hypertension than those patients without evidence of RV 
dysfunction on echocardiography. These results support the need for a clinical pathway to 
refer rule-positive patients for screening with echocardiography followed by evaluation in a 
multidisciplinary dyspnea clinic.
4.1. Limitations
This study analyzed a subset of patients from a previously collected sample where ordering 
an echocardiogram was not standardized but was ordered at the discretion of the treating 
physician. The patients may have had characteristics or severity of symptoms not easily 
identified by a secondary analysis, which persuaded clinicians to order the echocardiogram. 
Also, this was a multi-institution study with a lot of intrinsic variation, especially with 
availability of echocardiography among these institutions. Therefore, there was some 
selection bias in the patients who had an echocardiogram performed, as these patients were 
older and sicker.
Findings on echocardiography were divided into 5 categories as listed in the Methods 
section. It is possible that some patients included in the moderate to severe TR subgroup 
may have also had evidence of RV dysfunction and not recorded as such. As previous 
literature has shown, moderate to severe TR has a high correlation with RV dysfunction 
and/or dilation [23]. Thus, the prevalence of RV dysfunction may be underestimated and 
may actually be larger than 19%. We also defined isolated RV dysfunction or overload on 
echocardiography as evidence of RV dysfunction without concurrent LV systolic 
dysfunction. Because this was a secondary analysis of previously collected data, we lacked 
echocardiographic information on LV diastolic function, as this was not recorded in the 
original data set. In light of this, the prevalence of isolated RV dysfunction may actually be 
less than 33%. Lastly, there were no sample size calculations because this was a secondary 
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analysis. We had a small sample size of 198 patients, which is the result of a subset analyses 
from a much larger data set and therefore have larger CIs. A prospective study of 
echocardiogram findings in all cases of persistent dyspnea and negative CTPA might find a 
different prevalence of isolated RV dysfunction or overload with smaller CIs.
5. Conclusions
In an independent sample, RV dysfunction or overload has a prevalence of 19% in patients 
with persistent shortness of breath with a non-significant CTPA. In the subset of patients 
with preserved LVEF, the prevalence of isolated RV dysfunction or overload increases to 
33%. Among patients selected for echocardiography based on standard clinical judgment, 
this CDR predicts significant risk for isolated RV dysfunction or overload, higher 
recidivism, and worsened outcomes. These data suggest a need for wider use of 
echocardiography to screen this subset of patients for RV dysfunction or overload and a need 
for specialist referral to identify treatable causes of RV dysfunction or overload. Future goals 
will be to prospectively validate this rule in the ED setting, with a next step of using bedside 
ultrasound to further risk stratify these patients.
References
1. Pitts SR, Niska RW, Xu J, Burt CW. National Hospital Ambulatory Medical Care Survey: 2006 
emergency department summary. National health statistics reports. 2008:1–38.
2. Kline JA, Shapiro NI, Jones AE, Hernandez J, Hogg MM, Troyer J, et al. Outcomes and radiation 
exposure of emergency department patients with chest pain and shortness of breath and ultralow 
pretest probability: a multicenter study. Ann Emerg Med. 2013; 63:281–8. [PubMed: 24120629] 
3. Samad Z, Hakeem A, Mahmood SS, Pieper K, Patel MR, Simel DL, et al. A meta-analysis and 
systematic review of computed tomography angiography as a diagnostic triage tool for patients with 
chest pain presenting to the emergency department. J Nucl Cardiol. 2012; 19:364–76. [PubMed: 
22322526] 
4. Gallagher MJ, Raff GL. Use of multislice CT for the evaluation of emergency room patients with 
chest pain: the so-called “triple rule-out”. Catheter Cardiovasc Interv. 2008; 71:92–9. [PubMed: 
18098208] 
5. Richman PB, Courtney DM, Friese J, Matthews J, Field A, Petri R, et al. Prevalence and 
significance of nonthromboembolic findings on chest computed tomography angiography 
performed to rule out pulmonary embolism: a multicenter study of 1,025 emergency department 
patients. Acad Emerg Med. 2004; 11:642–7. [PubMed: 15175202] 
6. Kline JA, Courtney DM, Beam DM, King MC, Steuerwald M. Incidence and predictors of repeated 
computed tomographic pulmonary angiography in emergency department patients. Ann Emerg 
Med. 2009; 54:41–8. [PubMed: 18838194] 
7. Zakir RM, Al-Dehneh A, Maher J, Saric M, Berkowitz RL. Right ventricular failure in patients with 
preserved ejection fraction and diastolic dysfunction: an underrecognized clinical entity. Congest 
Heart Fail. 2007; 13:164–9. [PubMed: 17541311] 
8. Lang IM, Plank C, Sadushi-Kolici R, Jakowitsch J, Klepetko W, Maurer G. Imaging in pulmonary 
hypertension. J Am Coll Cardiol Img. 2010; 3:1287–95.
9. Rao S, Tate DA, Stouffer GA. Hemodynamic findings in severe tricuspid regurgitation. Catheter 
Cardiovasc Interv. 2013; 81:162–9. [PubMed: 22566375] 
10. Chaouat A, Weitzenblum E, Krieger J, Oswald M, Kessler R. Pulmonary hemodynamics in the 
obstructive sleep apnea syndrome. Results in 220 consecutive patients. Chest. 1996; 109:380–6. 
[PubMed: 8620709] 
11. Dumitrascu R, Tiede H, Eckermann J, Mayer K, Reichenberger F, Ghofrani HA, et al. Sleep apnea 
in precapillary pulmonary hypertension. Sleep Med. 2013; 14:247–51. [PubMed: 23340085] 
Russell et al. Page 8
Am J Emerg Med. Author manuscript; available in PMC 2020 February 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
12. van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, et al. 
Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension 
responding to therapy. J Am Coll Cardiol. 2011; 58:2511–9. [PubMed: 22133851] 
13. Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, et al. Right heart 
adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol. 
2013; 62:D22–33. [PubMed: 24355638] 
14. Piazza G, Goldhaber SZ. The acutely decompensated right ventricle: pathways for diagnosis and 
management. Chest. 2005; 128:1836–52. [PubMed: 16162794] 
15. Maron BA, Choudhary G, Khan UA, Jankowich MD, McChesney H, Ferrazzani SJ, et al. Clinical 
profile and underdiagnosis of pulmonary hypertension in US veteran patients. Circ Heart Fail. 
2013; 6:906–12. [PubMed: 23811965] 
16. Chen AA, Wood MJ, Krauser DG, Baggish AL, Tung R, Anwaruddin S, et al. NT-proBNP levels, 
echocardiographic findings, and outcomes in breathless patients: results from the ProBNP 
Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. 
Eur Heart J. 2006; 27:839–45. [PubMed: 16510467] 
17. Kline JA, Russell FM, Lahm T, Mastouri R. Derivation of a screening tool to identify patients with 
right ventricular dysfunction or tricuspid regurgitation after negative computerized tomographic 
pulmonary angiography. Pulm Circ. 2015:27.
18. Kline JA, Courtney DM, Kabrhel C, Moore CL, Smithline HA, Plewa MC, et al. Prospective 
multicenter evaluation of the pulmonary embolism rule-out criteria. J Thromb Haemost. 2008; 
6:772–80. [PubMed: 18318689] 
19. Kline JA, Johnson CL, Webb WB, Runyon MS. Prospective study of clinician-entered research 
data in the emergency department using an Internet-based system after the HIPAA Privacy Rule. 
BMC Med Inform Decis Mak. 2004; 4:17. [PubMed: 15479471] 
20. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, 
part II: pathophysiology, clinical importance, and management of right ventricular failure. 
Circulation. 2008; 117:1717–31. [PubMed: 18378625] 
21. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J. 2008; 
32:1371–85. [PubMed: 18978137] 
22. Wells JM, Washko GR, Han MK, Abbas N, Nath H, Mamary AJ, et al. Pulmonary arterial 
enlargement and acute exacerbations of COPD. N Engl J Med. 2012; 367:913–21. [PubMed: 
22938715] 
23. Mutlak D, Aronson D, Lessick J, Reisner SA, Dabbah S, Agmon Y. Functional tricuspid 
regurgitation in patients with pulmonary hypertension: is pulmonary artery pressure the only 
determinant of regurgitation severity? Chest. 2009; 135:115–21. [PubMed: 18719061] 
Russell et al. Page 9
Am J Emerg Med. Author manuscript; available in PMC 2020 February 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure. 
Flow diagram of patients meeting inclusion criteria.
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Table 1
Patient characteristics
Echo (n = 198) No echo (n =2418) Pa
Demographics
 Age (y) 60 ± 17 51 ± 18 <.05
 Male 83 (42) 716 (30) <.05
 BMI (kg/m2) 30 ± 9 30 ± 9 .439
Ethnicity
 White 117 (59) 1362 (57) .45
 Black 68 (34) 853 (35) .791
 Other 13 (7) 203 (8) .368
Vital signs
 Highest heart rate (beats/min) 103 ± 26 94 ± 22 <.05
 Systolic blood pressure (mm Hg) 128 ± 28 132 ± 25 .058
 Respiratory rate (breaths/min) 23 ± 6 22 ± 5 <.05
 Oxygen saturation (%) 94 ± 6 96 ± 4 <.05
 Temperature (°F) 98 ± 1 98 ± 1 .379
Associated symptoms
 Wheezing 36 (18) 345 (14) .795
 Chest pain at rest 49 (25) 1134 (47) <.05
 Prior visit for same symptoms 64 (32) 563 (23) .268
Comorbidities
 Chronic lung disease 60 (30) 637 (26) .867
 Tobacco use 84 (42) 899 (37) .142
 Hematologic disease 2 (1) 54 (2)
 CHF 16 (8) 53 (2) <.05
 Hypertension 117 (59) 940 (39) <.05
 CAD 46 (23) 267 (11) <.05
 Connective tissue disease 7 (4) 107 (4) .555
 PE or DVT 27 (14) 331 (14) .285
 CKD on HD 7 (4) 28 (1) <.05
 Diabetes 55 (28) 330 (14) <.05
 CVA 19 (10) 96 (4) <.05
 Anxiety 17 (9) 274 (11) .237
 Malignancy 35 (18) 378 (16) .448
Disposition
 ICU 19 (10) 48 (2) <.05
 Telemetry bed 121 (62) 633 (26) <.05
 Unmonitored bed 35 (18) 325 (13) .096
 Observation 8 (4) 270 (11) .002
 Discharge 12 (6) 1142 (48) <.05
Data presented as number (percent) and mean ± SD. Bold numbers are values reaching statistical significance (P < .05).
Am J Emerg Med. Author manuscript; available in PMC 2020 February 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Russell et al. Page 12
Abbreviations: BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; Chronic lung disease, chronic obstructive 
pulmonary disease, asthma, and interstitial lung disease; CKD, chronic kidney disease; CVA, cerebrovascular disease; DVT, deep venous 
thrombosis; HD, hemodialysis.
aP values from unpaired t test or χ2 test.
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Table 2
Comparison of patients with and without RV dysfunction on echocardiography
RVD (n = 38) No RVD (n = 160) Pa
Demographics
 Age (y) 63 ± 18 59 ± 17 .193
 Male 18 (47) 65 (41) .449
 BMI (kg/m2) 29 ± 7 30 ± 9 .286
Ethnicity
 White 25 (66) 92 (58) .35
 Black 10 (26) 58 (36) .246
 Other 3 (8) 10 (6) .713
Associated symptoms
 Wheezing 10 (26) 26 (16) .148
 Chest pain at rest 8 (21) 41 (26) .557
 Prior visit for same symptoms 12 (32) 52 (33) .913
Comorbidities
 Chronic lung disease 13 (34) 47 (29) .809
 Tobacco use 20 (53) 64 (40) .156
 CHF 12 (32) 37 (23) .165
 Hypertension 23 (61) 94 (59) .841
 CAD 13 (34) 33 (21) .074
 PE or DVT 7 (18) 20 (13) .339
 CKD on HD 2 (5) 5 (3) .521
 Diabetes 10 (26) 45 (28) .822
 Anxiety 3 (8) 14 (9) .865
 Malignancy 7 (18) 28 (18) .893
Disposition
 ICU 7 (18) 12 (8) .039
 Telemetry bed 23 (60) 101 (63) .765
 Unmonitored bed 4 (11) 31 (19) .198
 Observation 1 (3) 7 (4) .623
 Discharge 3 (8) 9 (6) .598
Abbreviations: BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; Chronic lung disease, chronic obstructive 
pulmonary disease, asthma, and interstitial lung disease; CKD, chronic kidney disease; DVT, deep venous thrombosis; HD, hemodialysis; RVD, RV 
dysfunction.
aP values from unpaired t test or χ2 test. Data presented as number (percent) and mean± SD.
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Table 3
Patient outcomes with normal LVEF
RVD (n = 38) No RVD (n = 77) Pa
Mortality 6 (16) 4 (5) .117
Return visits 15 (39) 14 (18) .013
Repeat CTPA 4 (10) 4 (5) .290
Final diagnosis
 COPD 8 (21) 8 (10) .120
 Asthma 1 (3) 3 (4) .727
 ILD 2 (5) 2 (3) .463
 Pneumonia 5 (13) 8 (10) .659
 CHF 7 (18) 12 (16) .730
 MI 1 (3) 1 (1) .607
 Sepsis 1 (3) 0 (0) .152
 Chest pain 3 (8) 14 (18) .143
 Pulmonary HTN 9 (24) 0 (0) <.05
 Other 10 (26) 37 (48) .025
Data presented as number (percent). Other included dyspnea, valvular heart disease, syncope, acute bronchitis, pleural effusion, cancer, atrial 
dysrhythmias, anemia, hypertensive emergency, scleroderma, sleep apnea, renal failure, and pericarditis. Abbreviations: CHF= congestive heart 
failure; COPD, chronic obstructive pulmonary disease; CTPA, computed tomography pulmonary angiography; HTN, hypertension; ILD, interstitial 
lung disease; MI, myocardial infarction; RVD, RV dysfunction.
aP values from unpaired t test or χ2 test.
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